Analysts at Truist Securities admitted that the result for itepekimab, which the companies were hoping to follow their ...

Pharmacokinetics: The pharmacokinetic profile of DF-003 was largely dose proportional and the data support additional clinical trials as a once-daily, orally administered drug.